Bruce Robinson, MD, PhD

Directed FDA regulatory review processes for Schedule 1 (C1) therapeutics (lysergide d-tartrate; MindMed) targeting DSM-5 disorders (GAD, MDD, AUD), developing critical stigma amelioration and commercialization strategies.

Assessed and advised on strategic marketing imperatives for clients (Biogen, TEVA) for therapeutic placement, marketing, and medical affairs campaigns, creating heuristic content and promotional reviews.

Developed and implemented company-wide educational platforms and lectures on new client therapeutics (MOA) and associated disease states (MOD) for all education levels, enhancing internal and external understanding.

Provided medical supervisory direction for onboarding HCB staff to clients' therapeutics and disease states, serving as client-facing representative for pitches and strategic AOR direction for launches.

Oversaw launches for rare diseases (Alport Syndrome, inherited retinal diseases) and genetic testing protocols, and non-opioid analgesia, aligning messaging with label and marketing strategies.

Served as a key New Business Development point person (Arvelle, Acquestive, Y-mAbs), contributing significantly to new client acquisitions and growth.

Developed company-wide educational platforms on new clients' therapeutics (MOA) and disease states (MOD) for all education levels, enhancing organizational expertise.

Enhanced Cimzia (psoriasis; UCB) Veeva platform through re-skim and playbook development, adding new indications and revamping KPIs to optimize digital engagement and content delivery.

Led global HCP launch initiatives for US GSK's Shingrix (no.1 selling vaccine in 2018) and Relvar Ellipta for European markets, overseeing strategic and content development for multi-channel consistency.

Developed and aligned creative with didactic content across print ads, direct mail, customized Veeva sales platforms, and website assets, ensuring optimal market penetration and brand messaging.

Developed an innovative DTC patient education platform for Array's first oncology product launch (Braftovi + Mektovi), focusing on PFS-extending therapeutic combinations for specific patient types.

Collaborated with and guided Array's Brand Teams and two marketing agencies (Cult, BioLumina) to align strategic imperatives for patient-level education content, ensuring consistent messaging.

Resolved complex regulatory content challenges through creative “word-smithing,” securing final upper-level approval and connecting patient tools to brand sciences and therapeutic benefits.

Developed and transformed the Medical Editorial Department, enabling the agency's shift to medical sciences and pharmaceutical clients, contributing to its recognition as “BEST SMALL AGENCY of the year” for two consecutive years.

Managed all medical sciences, client strategies, creative writing, and account responsibilities, serving as the final filter for content quality and alignment.

Drove organic account development, securing over $4 million in new accounts, including CAR-T from Novartis and abemaciclib from Eli Lilly, through personal POVs and client interaction.

Established an in-house “Foundry” (internal think tank) and led new sciences reviews, optimizing agency capabilities and deliverable strategies for potential clients.

Provided medical marketing and strategy supervision, ensuring alignment to SOWs and enriching product stories across the Fingerpaint community.

Positioned clients for payer strategies, formulary placement, and optimal contractual pricing plans, contributing to $6.3 million in deliverables across six new launches and three FDA-designated Breakthrough Therapies.

Leveraged high-sciences knowledge from Clinical Trials profiles to assist in language for label and FDA regulatory review for marketing roll-out.

Served as the final filter for all copy from Copywriters and Creative, ensuring alignment with brand story and functionality, while mentoring junior writers.

Developed medical content for branded and unbranded efforts, participating in medicolegal client reviews as agency representative and client point person.

Played a decisive role in developing Vertex's INCIVEK Mobile App (DTP/hep C), reworking the Interactive Treatment Algorithm and Drug Interactions channels, necessitating updates to the INCIVEK PI and Treatment Management Guide.

Received commendation from Ignite Health (Vertex Board Product Team) for contributions to key projects, demonstrating exceptional performance.

Authored therapeutic overviews for team onboarding on new disease states and therapeutic competitors, optimizing messaging and strategy for client products, marketing position, and key deliverables.

Conducted numerous on-locale medico-legal reviews as author/writer and contributed as a sciences expert to pitch development.